genus-claim
2 cases — ← All topics
| Case | Title | Lower Court | Docketed | Status | Flags | Tags | Question Presented |
|---|---|---|---|---|---|---|---|
| 24A1215 | MSN Pharmaceuticals, Inc., et al v. Novartis Pharmaceuticals Corporation | Federal Circuit | 2025-06-10 | Presumed Complete | after-arising-technology enablement-doctrine federal-circuit genus-claim patent-law patent-validity | Whether a patent may validly claim a genus without describing or enabling species of the genus that utilize after-arising technology | |
| 20-380 | Idenix Pharmaceuticals LLC, et al. v. Gilead Sciences, Inc. | Federal Circuit | 2020-09-24 | Denied | Amici (3)Response RequestedResponse WaivedRelisted (2) | 35-usc-112a enablement genus-claim genus-claims patent patent-law pharmaceutical-innovation pharmaceuticals statutory-interpretation written-description | Whether the Federal Circuit's genus-claim-specific enablement rule and separate 'possession' requirement are consistent with 35 U.S.C. § 112(a) |